Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Chimerix: Upgrading the Stock to a Buy (CMRX. Buy, $6.10)

Definitions of Key Words

This section defines a number of words, phrases and acronyms that I have used in this report…
Read more…

Chimerix: An Update (CMRX, $52.83, Neutral)

Company Description

Chimerix is focused on the development and commercialization of antiviral drugs. Its lead product brincidofovir is a phospholipid derivative…
Read more…

Chimerix: Moving to a Buy (CMRX, $14.22, Paid subscribers)

Investment Thesis

I wrote a major report on Chimerix on March 13, 2014. I had been working on the report for…
Read more…

Chimerix is A Company Focused on Infectious Viral Diseases that Has Investment Characteristics Similar to Trius (CMRX, Neutral, $25.48) (Subscribers Only)

Report In Brief
This report is an in-depth analysis of Chimerix (CMRX). I like the fundamental outlook of this company very…
Read more…